GLP-1 Peptide Dosage: How to Read, Calculate & Understand Your Dose

GLP-1 dosing is where most confusion starts.

Key Takeaways

• The core confusion: Doses are expressed in mg, but syringes measure in ml or units — the conversion is simple but trips people up constantly.
• Autoinjector pens: Pre-set dose, no calculation needed — click, inject, done. This covers branded Wegovy, Ozempic, Zepbound, and Mounjaro pens.
• Vial and syringe: You must calculate volume. The formula is dose (mg) ÷ concentration (mg/ml) = volume (ml). Know your vial's concentration before calculating.
• Semaglutide titration: 0.25mg → 0.5mg → 1mg → 1.7mg → 2.4mg, each step lasting approximately 4 weeks.
• Tirzepatide titration: 2.5mg → 5mg → 7.5mg → 10mg → 12.5mg → 15mg, each step lasting approximately 4 weeks.
• Honest caveat: This is general reference information — your prescriber's specific instructions always take priority over general guides.

People starting GLP-1 therapy on autoinjector pens rarely need to think about dosage math — the pen does it for them. But a meaningful number of patients use vials and syringes, either through compounded formulations or in clinical settings, and for them the conversion between milligrams, milliliters, and syringe units is a daily practical question with real consequences for getting the right dose. This guide walks through the titration schedules for the major GLP-1 drugs, the math for calculating volumes, and the answers to the questions that come up most often.

Why the dosing system is confusing

The confusion is structural, not personal.

GLP-1 drugs are prescribed with doses expressed in milligrams (mg) — a weight measurement. But the liquid you draw into a syringe is measured in milliliters (ml) — a volume measurement. These are different things. The same mg dose can correspond to very different ml volumes depending on how concentrated the solution is.

A vial labeled 5mg/2ml contains 2.5mg per ml. A vial labeled 10mg/2ml contains 5mg per ml. If you're drawing a 0.25mg dose, these two concentrations require very different volumes — 0.1ml from the first, and 0.05ml from the second. Getting this wrong by even a small amount means consistently over- or under-dosing.

On top of this, insulin syringes — which are commonly used to inject GLP-1 solutions from vials — are marked in units rather than milliliters. One unit on a standard U-100 insulin syringe equals 0.01ml. So 0.1ml is 10 units, and 0.05ml is 5 units. Converting from mg to ml to units involves two steps. Neither step is difficult, but together they create a system that confuses people who have never had to do syringe math before.

Autoinjector pens: the simple case

Pre-set pens require no calculation.

Branded GLP-1 autoinjector pens — Wegovy, Ozempic, Zepbound, Mounjaro, Saxenda, Victoza — are designed to deliver a specific, pre-set dose with each click. You select the pen appropriate for your current dose step, attach a needle, dial or prime as instructed, inject subcutaneously, and you are done. There is no vial, no syringe, no math.

Each Wegovy pen is pre-filled for a specific dose: 0.25mg, 0.5mg, 1mg, 1.7mg, or 2.4mg. When your prescriber moves you to the next dose step, you receive the corresponding pen. The system is engineered to make titration straightforward: you always know you're getting the right dose because the pen is pre-configured for it.

For patients who use autoinjector pens, the rest of this article is reference material for understanding what's happening pharmacologically — not a set of calculations you need to run yourself.

Vial and syringe: the calculation you actually need

One formula handles every calculation.

Volume (ml) = Dose (mg) ÷ Concentration (mg/ml)

That's it. Every dose calculation for a vial-and-syringe GLP-1 setup reduces to this formula. To use it, you need two pieces of information: the dose your prescriber specified, and the concentration of your specific vial. Both should be on your prescription and on the vial label.

Here are worked examples using common concentrations:

If you're unsure about your vial's concentration, look at the label carefully. The format will be something like "5mg/ml" or "10mg/2ml" — the second format means you need to divide to get mg/ml (10 ÷ 2 = 5mg/ml). Never estimate concentration. If the label is unclear or you received a vial without concentration information, contact your prescriber or pharmacist before drawing any dose.

Semaglutide titration schedule in full

The titration exists to protect your GI system.

The dose escalation schedule for semaglutide is designed to allow the gut to adapt to progressively stronger GLP-1 receptor activation. Each step up increases the therapeutic effect — and the potential for nausea and other GI symptoms. Moving through the schedule at the recommended pace, rather than accelerating it, dramatically reduces dropout rates from side effects.

Standard Wegovy (semaglutide for obesity) titration:

• Weeks 1–4: 0.25mg once weekly — tolerance-building dose; minimal therapeutic appetite suppression at this level

• Weeks 5–8: 0.5mg once weekly — first meaningful dose step; some appetite change noticeable

• Weeks 9–12: 1mg once weekly — mid-range dose; appetite suppression meaningfully increases

• Weeks 13–16: 1.7mg once weekly — penultimate step; most patients notice significant appetite reduction here

• Weeks 17+: 2.4mg once weekly — maintenance dose used in clinical trials; maximum FDA-approved dose

Ozempic (semaglutide for T2D) follows the same initial steps but has a maximum approved dose of 2mg rather than 2.4mg. The steps are: 0.25mg (weeks 1–4) → 0.5mg (weeks 5+) → 1mg if additional A1c reduction is needed → 2mg if further improvement is warranted. The 2.4mg obesity dose is not part of the Ozempic approved range.

Some prescribers slow the titration for patients who experience significant side effects at any step — spending 8 weeks at a given dose instead of 4 before advancing. This is clinically appropriate and does not indicate that the drug isn't working. It indicates that the patient needs a longer adjustment window, which is common and manageable.

Liraglutide (Saxenda) titration

Saxenda uses a daily injection schedule, not weekly.

Because liraglutide has a shorter half-life than semaglutide (approximately 13 hours vs. 7 days), it requires daily dosing to maintain consistent drug levels. The titration escalates weekly:

• Week 1: 0.6mg once daily

• Week 2: 1.2mg once daily

• Week 3: 1.8mg once daily

• Week 4: 2.4mg once daily

• Week 5+: 3mg once daily (maintenance dose)

If GI side effects are significant at any escalation step, many providers recommend holding at the lower dose for an additional week before advancing. The 3mg maintenance dose is what was tested in the SCALE clinical trials, which showed approximately 8% body weight reduction — less than semaglutide or tirzepatide, which is part of why Saxenda is less commonly prescribed as a first choice in 2026 when more effective options are available and accessible.

Tirzepatide (Mounjaro/Zepbound) titration

Tirzepatide follows a longer escalation path.

Because tirzepatide acts on two receptors simultaneously — GLP-1 and GIP — it produces a stronger combined signal at each dose. The titration moves more slowly to allow adaptation:

• Weeks 1–4: 2.5mg once weekly (starting dose)

• Weeks 5–8: 5mg once weekly

• Weeks 9–12: 7.5mg once weekly

• Weeks 13–16: 10mg once weekly

• Weeks 17–20: 12.5mg once weekly

• Weeks 21+: 15mg once weekly (maximum dose)

Clinical trials (SURMOUNT-1 for obesity) showed approximately 22.5% body weight reduction at the maximum 15mg dose over 72 weeks. The 10mg dose produced approximately 19.5%, and the 5mg dose approximately 15.7%. This dose-response relationship explains why the full titration to maximum dose matters: meaningful additional weight loss continues at each escalation step.

Not everyone needs to reach the maximum dose of either drug. Some patients achieve their weight and metabolic goals at a lower maintenance dose. There is no clinical requirement to escalate to maximum if you're achieving your therapeutic goal at a lower dose with fewer side effects. This is worth discussing explicitly with your provider rather than assuming you need to reach the top dose.

How to handle a missed dose

Missing a weekly injection happens — the protocol is clear.

For semaglutide (Wegovy or Ozempic): if you miss an injection, take it as soon as you remember — as long as your next scheduled dose is at least 2 days (48 hours) away. If it has been more than 5 days since the missed dose, skip it entirely and resume your regular schedule on the next scheduled injection day. Do not take two doses to make up for the missed one.

For tirzepatide (Mounjaro or Zepbound): similar approach. Take the missed dose within 4 days of when it was scheduled. If more than 4 days have passed, skip the missed dose and resume your regular schedule. Do not double-dose.

For liraglutide (Saxenda), which is daily: if you miss a day, skip it and resume the next day. Do not take two doses the following day to compensate.

One practical note: if you miss doses frequently, it's worth addressing the reason with your provider. Consistent weekly injection on a set schedule is what maintains steady drug levels and the therapeutic effect. Inconsistent dosing produces variable drug levels and less predictable appetite suppression.

The honest caveat

This guide is accurate general reference information — your prescriber's instructions are the authority.

Titration schedules can vary based on your individual response, tolerability, and the specific formulation you're using. Some patients are held at a lower dose longer due to side effects; others have their schedule modified for clinical reasons. Compounded formulations may have different concentrations than the examples in this guide. Your prescriber and pharmacist are the primary sources for dose-specific instructions that apply to your situation. This article helps you understand the system — it does not replace clinical guidance tailored to you specifically.

Frequently Asked Questions

Can I go faster through the titration if I feel fine at the starting dose?
Your prescriber may allow it in some circumstances, but it is generally not recommended. The titration schedule is based on GI tolerability, and many patients who feel fine at the starting dose develop significant nausea when the dose jumps too quickly. Clinical dropout rates are higher in populations that accelerate titration. Unless your prescriber specifically recommends a faster schedule for a clinical reason, the standard pacing is the better choice.

What if I can't tolerate a dose step and need to go back down?
This is common and expected. If a dose escalation produces intolerable GI side effects, stepping back to the previous dose for an additional 4 weeks before re-attempting the escalation is standard clinical practice. Some patients spend 8–12 weeks at a given dose step before tolerating the next one. This extends the overall titration timeline but is far better than stopping treatment entirely.

How do I know if my vial concentration is correct?
Check both the vial label and your prescription documentation. They should match. If you received a vial without clear concentration labeling, contact the pharmacy or compounding facility immediately before using the medication. Never draw from a vial you cannot confirm the concentration of.

What size syringe should I use for subcutaneous GLP-1 injection?
A standard insulin syringe — typically 0.5ml or 1ml capacity, 28–31 gauge needle — is commonly used for subcutaneous GLP-1 injection from a vial. The appropriate syringe size depends on the volume you're drawing. For small volumes (0.05–0.1ml), a 0.3ml or 0.5ml syringe with fine graduations allows more accurate measurement than a 1ml syringe. Your prescriber or pharmacist can recommend the appropriate syringe type for your dose and concentration.

Where are subcutaneous GLP-1 injections administered?
The three standard sites for subcutaneous injection are the abdomen (at least two inches from the navel), the outer thigh, and the back of the upper arm. Rotating sites with each injection reduces the risk of lipohypertrophy — a thickening of the fat tissue at injection sites that can occur with repeated injection in the same spot. Do not inject into muscle. Inject into the fatty tissue just under the skin.

This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before starting any medication.